Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report

被引：4

作者：

Aubanel, Marjorie ^{[1
]}

Swalduz, Aurelie ^{[1
]}

Avrillon, Virginie ^{[1
]}

Doublet, Louis ^{[1
]}

Mastroianni, Benedicte ^{[1
]}

Neidhardt-Berard, Eve-Marie ^{[1
]}

Perol, Maurice ^{[1
]}

机构：

[1] Ctr Leon Berard, Dept Med Oncol, 28 Rue Laennec, F-69008 Lyon, France

来源：

CLINICAL LUNG CANCER | 2020年 / 21卷 / 06期

关键词：

Combination targeted therapies; EGFR TKI; Lung cancer; MET amplification; Resistance; NSCLC PATIENTS; CANCER; ERLOTINIB; COMBINATION; OSIMERTINIB; RESISTANCE; PATIENT;

D O I：

10.1016/j.cllc.2020.05.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：E601 / E606

页数：6

共 26 条

[1] Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors [J].

Baldacci, Simon ;

Mazieres, Julien ;

Tomasini, Pascale ;

Girard, Nicolas ;

Guisier, Florian ;

Audigier-Valette, Clarisse ;

Monnet, Isabelle ;

Wislez, Marie ;

Perol, Maurice ;

Do, Pascal ;

Dansin, Eric ;

Leduc, Charlotte ;

Leprieur, Etienne Giroux ;

Moro-Sibilot, Denis ;

Tulasne, David ;

Kherrouche, Zoulika ;

Labreuche, Julien ;

Cortot, Alexis B. .

ONCOTARGET, 2017, 8 (62) :105103-105114

[2] MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer [J].

Camidge, D. Ross ;

Davies, Kurtis D. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (11) :855-+

[3] CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib [J].

Costa, Daniel B. ;

Kobayashi, Susumu ;

Pandya, Shuchi S. ;

Yeo, Wee-Lee ;

Shen, Zhongzhou ;

Tan, Weiwei ;

Wilner, Keith D. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) :E443-E445

[4] Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met-Amplified Adenocarcinoma of the Lung [J].

Dietrich, Martin Frederik ;

Yan, Shirley Xiao ;

Schiller, Joan Hoff .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (05) :E23-E25

[5] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Mitsudomi, Tetsuya ;

Song, Youngchul ;

Hyland, Courtney ;

Park, Joon Oh ;

Lindeman, Neal ;

Gale, Christopher-Michael ;

Zhao, Xiaojun ;

Christensen, James ;

Kosaka, Takayuki ;

Holmes, Alison J. ;

Rogers, Andrew M. ;

Cappuzzo, Federico ;

Mok, Tony ;

Lee, Charles ;

Johnson, Bruce E. ;

Cantley, Lewis C. ;

Janne, Pasi A. .

SCIENCE, 2007, 316 (5827) :1039-1043

[6] Dramatic Response to. Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification [J].

Gainor, Justin F. ;

Niederst, Matthew J. ;

Lennerz, Jochen K. ;

Dagogo-Jack, Ibiayi ;

Stevens, Sara ;

Shaw, Alice T. ;

Sequist, Lecia V. ;

Engelman, Jeffrey A. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) :E83-E85

[7] Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer [J].

Lara, Matthew S. ;

Holland, William S. ;

Chinn, Danielle ;

Burich, Rebekah A. ;

Lara, Primo N., Jr. ;

Gandara, David R. ;

Kelly, Karen ;

Mack, Philip C. .

CLINICAL LUNG CANCER, 2017, 18 (03) :281-285

[8] Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C [J].

Li, Y. Q. ;

Song, S. S. ;

Jiang, S. H. ;

Zhang, X. Y. .

ANNALS OF ONCOLOGY, 2017, 28 (10) :2622-2624

[9] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer [J].

Mok, T. S. ;

Wu, Y. -L. ;

Ahn, M. -J. ;

Garassino, M. C. ;

Kim, H. R. ;

Ramalingam, S. S. ;

Shepherd, F. A. ;

He, Y. ;

Akamatsu, H. ;

Theelen, W. S. M. E. ;

Lee, C. K. ;

Sebastian, M. ;

Templeton, A. ;

Mann, H. ;

Marotti, M. ;

Ghiorghiu, S. ;

Papadimitrakopoulou, V. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) :629-640

[10] Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSe Trial [J].

Moro-Sibilot, D. ;

Cozic, N. ;

Perol, M. ;

Otto, J. ;

Mazieres, J. ;

Souquet, P. ;

Bahleda, R. ;

Wislez, M. ;

De Guibert, S. ;

Mennecier, B. ;

Chouaid, C. ;

Sabatier, R. ;

Bota, S. ;

Gervais, R. ;

Verriele, V. ;

Haddad, V. ;

Ferretti, G. ;

Nowak, F. ;

Oukhatar, C. Mahier-Ait ;

Vassal, G. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S348-S348

← 1 2 3 →